CDMO Capacity Expansion in North America: Peptide Manufacturing Investment Hits Five-Year High in 2026

North American CDMOs are investing at a five-year-high rate to expand peptide manufacturing capacity in 2026, driven by sustained GLP-1 demand and the near-shoring of supply chains following 2022-2023 shortages. Capital expenditure commitments by the top 10 North American peptide CDMOs reached approximately $4.2 billion cumulatively through Q1 2026 against 2024-2026 project timelines. For organizations monitoring industry trends and procurement planning, understanding which facilities are coming online and when will be a critical supply chain input through 2027-2028.

The Investment Wave

Peptide manufacturing capacity expansion in North America entered a high-investment cycle beginning in late 2023, accelerated by three converging pressures: the sustained commercial demand for GLP-1 agonists that exceeded every pre-2022 supply projection, the explicit US government policy push for domestic pharmaceutical manufacturing capability, and the recognition by pharmaceutical sponsors that excessive concentration of peptide API supply in Asia-Pacific created unacceptable supply chain risk.

The result is a wave of CDMO capital projects, new facility constructions, large-scale reactor additions, SPPS capacity expansions, and purification infrastructure buildouts, that is now moving from planning to construction to commissioning across the US and Canada. At the same time, European CDMOs have expanded their North American presence through acquisitions and greenfield facilities, adding to the competitive landscape and total capacity available to North American sponsors.

Major Capacity Projects Now Underway

Several notable capacity expansion projects entered construction or commissioning phases in Q1-Q2 2026:

Large-scale GLP-1 synthesis capacity. Multiple CDMOs that have not been publicly identified (under confidentiality agreements with major pharmaceutical sponsors) are constructing GMP-grade SPPS facilities specifically scaled for the synthesis volumes required by approved GLP-1 products. These facilities are designed around 1,000-5,000 liter reactor equivalents, far larger than traditional SPPS for research or early clinical supply, reflecting the commercial manufacturing reality of GLP-1 drugs taken by millions of patients.

Oligopeptide purification infrastructure. Reverse-phase HPLC purification capacity, the primary purification method for peptide APIs, is a key bottleneck at current commercial scale. CDMO investments in preparative HPLC equipment have accelerated significantly. Industry sources report that lead times for large-scale preparative HPLC systems from major suppliers (Novasep, Cytiva, Repligen, Agilent) extended to 18-24 months in 2023-2024, driving CDMOs to place forward orders and expand purchasing relationships to maintain project timelines.

Specialized formulation facilities. As oral peptide delivery advances toward commercial realization, CDMOs with oral formulation capability for peptides are investing in specialized equipment for SNAC-enhanced tablet production, lipid nanoparticle formulation, and the analytical infrastructure needed to characterize oral peptide products. This specialization requires different facility design than injectable peptide manufacturing and represents a distinct capacity build category from SPPS expansion.

Key North American CDMO Players Expanding

Without disclosing confidential project details, the publicly documented expansion activity includes several significant participants in the North American peptide CDMO market:

Bachem. The Swiss CDMO with significant US presence (San Diego and King of Prussia facilities) announced capacity expansion in 2025 and has been executing project milestones. Bachem's North American footprint is a strategic asset for sponsors seeking GMP-qualified API supply from an organization with decades of peptide manufacturing expertise.

Lonza. Lonza's peptide capabilities at its US sites continue to expand, with announcements in 2025 relating to SPPS capacity. Lonza's integration of peptide manufacturing with its broader CDMO network creates differentiated value for sponsors needing both peptide API and formulation services under a single contract.

PolyPeptide Group. The PolyPeptide Group, with both European and US manufacturing sites, has been actively expanding SPPS and purification capacity. Their San Diego facility has been a subject of public announcements relating to capacity additions.

Mid-size US CDMOs. A cohort of mid-size US CDMOs, Peptisyntha, CPC Scientific, AmbioPharm, have collectively been expanding capacity, with individual project announcements reflecting the broader market dynamic.

Workforce Implications of Capacity Expansion

Capital investment in new CDMO capacity creates immediate demand for qualified manufacturing personnel. The staffing market in peptide CDMO operations is extremely tight, and new facility commissioning faces a consistent challenge: equipment can be installed on a capital timeline, but qualified operators, quality personnel, and process development scientists cannot be hired and trained at the same pace.

The roles in highest demand at expanding CDMOs include:

• SPPS Operators and Senior SPPS Scientists with hands-on FMOC chemistry experience and cGMP documentation skills
• Purification Scientists with preparative HPLC method development and scale-up experience
• Quality Assurance / Quality Control professionals familiar with peptide-specific analytical methods (HPLC purity testing, mass spectrometry for identity confirmation, amino acid analysis)
• Manufacturing Process Engineers who can translate lab-scale SPPS procedures to GMP manufacturing scale

Compensation for these profiles has risen 18-28% over 2024 levels in active CDMO expansion markets (Boston-Cambridge, San Diego, Research Triangle Park, and the Philadelphia corridor). Signing bonuses of $20,000-$40,000 are now standard for experienced SPPS and purification scientists joining CDMO expansion projects, reflecting competition for a scarce talent pool.

Near-Shoring and Supply Chain Strategy

The CDMO capacity expansion in North America is partly driven by explicit near-shoring strategy among pharmaceutical sponsors. The COVID-19 supply chain disruptions revealed the fragility of API supply concentrated in a small number of geographies, and the regulatory pressure from US Section 301 tariffs and BIOSECURE Act discussions has accelerated the reassessment of China-based API sourcing for critical drugs.

For GLP-1 agonists specifically, which are now top-revenue products for Novo Nordisk and Eli Lilly and are approaching blockbuster status for multiple indication expansions, any supply disruption has material financial and patient care consequences. Sponsors have responded by qualifying multiple API suppliers, including North American sources, even at higher cost, as insurance against geographic concentration risk.

This strategy is visible in CDMO order books: North American CDMOs report that they are receiving qualification requests and audit visits from sponsors who previously sourced exclusively from Asian manufacturers. Converting these initial qualification engagements into long-term supply agreements is the commercial priority for North American CDMOs in 2026.

Regulatory Tailwinds Supporting Domestic Production

FDA's Manufacturing Site Inspection and approval processes have also been a factor. The COVID-era backlog of overseas facility inspections created qualification delays for some Asia-Pacific manufacturers, while domestic facilities maintained more consistent inspection timelines and access. For sponsors with FDA-approved products, the predictability of domestic inspection timelines has become a supply chain risk management consideration.

The regulatory compliance advantage of domestic manufacturing extends to audit access as well. Sponsors conducting quality audits of CDMO partners face no geographic barriers for North American facilities, while overseas facility audits require travel planning, regulatory permissions in some jurisdictions, and time zone and language considerations that add friction to quality assurance relationships.

Market Outlook Through 2028

The North American peptide CDMO market is projected to grow at a compound annual rate of 12-16% through 2028, with capacity expansion projects currently underway representing approximately 35-40% of the total capacity addition expected over this period. The remaining capacity growth will come from projects currently in planning that have not yet entered construction.

For industry trends planning purposes, the most important supply signal is that the commercial-scale capacity additions designed for GLP-1 manufacturing are not expected to create overcapacity even if GLP-1 demand growth moderates, the baseline demand for approved GLP-1 products already consumes or is committed to the majority of expansion capacity coming online in 2026-2027. Overcapacity risk is more relevant for clinical and early commercial scale operations, where the pipeline of new peptide programs seeking manufacturing partnerships has grown faster than capacity at CDMOs optimized for small-volume, high-complexity synthesis.

Organizations planning peptide CDMO partnerships for clinical programs should be establishing those relationships 18-24 months ahead of anticipated manufacturing start, as capacity reservation timelines at leading CDMOs have extended significantly from the 6-12 month norms of 2019-2021.